FORM 4

UNITED STATES SECUR

Washington, D.C. 20549

ΚI	ш	ES	ΑГ	טוי	EX	CH	ΑN	GE	CU	IVIIV	เมร	SI	U	N

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* IMRAN MIR A (Last) (First) (Middle) 2051 RINGWOOD AVE (Street)						2. Issuer Name and Ticker or Trading Symbol Rani Therapeutics Holdings, Inc. [RANI] 3. Date of Earliest Transaction (Month/Day/Year) 12/16/2024 4. If Amendment, Date of Original Filed (Month/Day/Year)							Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Delow) below) late of the person of the pe				
(City)	SAN JOSE CA 95131 (City) (State) (Zip)			-	Form filed by One Reporting Person Form filed by More than One Reporting Person									ng Person			
		7	Гable I - Non-	Deriva	tive S	Securiti	es Acq	uired, l	Disp	osed of,	or Bene	ficially (Owned				
Da				. Transac Date Month/Da	2A. Deemed Execution Date if any (Month/Day/Ye		on Date,	3. Transaction Code (Instr. 8)		es Acquired (A) or Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of ndirect Beneficial Dwnership	
							Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	onversion Date Exercise (Month/Day/Year) if an infancion of erivative		Code	saction e (Instr. E (Instr. Securities Acquired (A) Disposed of ((Instr. 3, 4 and		e s I (A) or d of (D)	Expiration Da (Month/Day/Y A) or of (D)		ate of Securities		es J Security	8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares		Transacti (Instr. 4)			
Stock Option (Right to Buy)	\$2.84	12/16/2024		D			101,276	05/25/20)24	05/24/2033	Class A Common Stock	101,276	(1)	0		D	
Stock Option (Right to Buy)	\$4.11	12/16/2024		A		101,276		05/25/20	024	05/24/2033	Class A Common Stock	101,276	(1)	101,2	76	D	

Explanation of Responses:

1. On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to \$4.11 per share. There is no change to the expiration dates or the vesting schedule of the options.

Svai Sanford. Attorney-in-Fact for Mir Imran

12/17/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.